Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia | Zendy

Kenneth L. Subotnik | Zendy; Laurie R. Casaus | Zendy; Joseph Ventura | Zendy; John Luo | Zendy; Gerhard Hellemann | Zendy; Denise GretchenDoorly | Zendy; Stephen R. Marder | Zendy; Keith H. Nuechterlein | Zendy

Open Access

Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia

Author(s) -

Kenneth L. Subotnik,

Laurie R. Casaus,

Joseph Ventura,

John Luo,

Gerhard Hellemann,

Denise GretchenDoorly,

Stephen R. Marder,

Keith H. Nuechterlein

Publication year - 2015

Publication title -

jama psychiatry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.531

H-Index - 365

eISSN - 2168-6238

pISSN - 2168-622X

DOI - 10.1001/jamapsychiatry.2015.0270

Subject(s) - risperidone , randomized controlled trial , schizophrenia (object oriented programming) , psychiatry , exacerbation , antipsychotic , medicine , relapse prevention , psychology , psychosis , atypical antipsychotic , pediatrics

Long-acting, injectable, second-generation antipsychotic medication has tremendous potential to bring clinical stability to persons with schizophrenia. However, long-acting medications are rarely used following a first episode of schizophrenia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog